Physician profile
Marie E Wehner
NPI 1295046175
$1,677.36
in general payments reported to CMS, 2019-2025
15 companies · $193 in 2025
The $193 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.35 · 2020: $22.83 · 2022: $253 · 2023: $259 · 2024: $920 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,373.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Menicon America INC | $824.11 | 2024 | |
| Glaukos Corporation | $321.07 | 2022-2025 | Idosetr, Istent Infinite |
| Horizon Therapeutics Plc | $138.67 | 2023 | Tepezza |
| Lkc Technologies, INC. | $71.53 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $66.37 | 2024 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $59.58 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $33.61 | 2023-2024 | Vyzulta |
| Alcon Vision LLC | $32.65 | 2023-2024 | Total30 |
| Allergan, INC. | $29.75 | 2022 | |
| Sight Sciences, INC. | $27.87 | 2022 | |
| Oyster Point Pharma, INC. | $21.43 | 2022 | |
| Shire North American Group INC | $17.02 | 2019 | |
| Coopervision INC. | $15.66 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.82 | 2023 | |
| Biotissue Holdings INC. | $5.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marie Wehner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.